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Scavenger receptor class B type I (SR-BI) protein is an integral membrane glycoprotein. SR-BI is 
emerging as a multifunctional protein, which regulates autophagy, efferocytosis, cell survival and 
inflammation. It is well known that SR-BI plays a critical role in lipoprotein metabolism by 
mediating cholesteryl esters selective uptake and the bi-directional flux of free cholesterol. 
Recently, SR-BI has also been identified as a potential marker for cancer diagnosis, prognosis, 
or even a treatment target. Natural products are a promising source for the discovery of new drug 
leads. Multiple natural products were identified to regulate SR-BI protein expression. There are 
still a number of challenges in modulating SR-BI expression in cancer and in using natural 
products for modulation of such protein expression. In this review, our purpose is to discuss the 
relationship between SR-BI protein and cancer, and the molecular mechanisms regulating SR-BI 
expression, as well as to provide an overview of natural products that regulate SR-BI expression. 
 





Scavenger receptor class B type I (SR-BI) protein was first isolated and identified by Calvo et al. 
[1] based on a sequence closely related to cluster of differentiation 36 (CD36) and lysosomal 
integral membrane protein (LIMP) analogous-1. The gene of human SR-BI located on 
chromosome 12, initially named CLA-1, now is called SCARB1 and comprises 13 exons and 12 
introns [2]. SR-BI protein is an 82 kDa integral membrane glycoprotein, which (together with LIMP-
2) is a member of CD36 superfamily of scavenger receptor proteins [3]. SR-BI has a hairpin-
looped structure with two short N- and C-terminal transmembrane domains, two cytoplasmic tails, 
and a large extracellular loop [4, 5]. A full-length human SR-BI protein contains 509 amino acids, 
of which a large extracellular domain (ECD) includes 408 amino acids, N- and C-terminal 
transmembrane domains include 22 and 23 amino acids respectively, as well as N- and C-
terminal cytoplasmic domain include 9 and 44 amino acids, respectively [6]. ECD contains 
multiple sites for N-linked glycosylation of SR-BI [6]. 
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With the conserved function across various species, SR-BI is expressed in many normal and 
hormonally altered tissues and cell types, including liver, brain, intestine, placenta, and 
steroidogenic tissues, as well as macrophages, endothelial cells, smooth muscle cells, 
keratinocytes and adipocytes [2, 7, 8]. SR-BI predominantly expresses in the liver and 
steroidogenic tissues (adrenal gland, gonads) [9-11]. A previous study suggests that SR-BI 
protein located in caveolae of ldlA7-SR-BI cells and murine adrenocortical Y1-BS1 cells based on 
partial colocalization with caveolin-1 [12]. It was reported, however, that SR-BI is majorly localized 
in clusters of microvillar extensions on the plasma membrane rather than caveolae [13]. 
Expression of recombinant SR-BI induced the formation of double-membraned channel structures, 
which increased the uptake of high-density lipoprotein-cholesteryl esters (HDL-CE) [14, 15].  
 
It was demonstrated that the SR-BI is critical to lipoprotein metabolism by mediating CE selective 
uptake and the bi-directional flux of free cholesterol [16]. SR-BI is emerging as a multifunctional 
receptor in different cellular types [2]. Hepatic SR-BI selectively takes up HDL-CE for the delivery 
of cholesterol to bile, which perseveres HDL functions, and is also critical in the clearance of 
remnant lipoproteins and lipoprotein(a) (Lp(a)) [2, 17]. SR-BI can facilitate the efflux of cholesterol 
from peripheral tissues including macrophages, then back to liver [17]. In addition, in human and 
mouse macrophages SR-BI influences autophagy [2]. In both macrophages and endothelial cells, 
SR-BI could also regulate signaling pathways involved in efferocytosis, cell survival, and 
inflammation [2]. It was shown that SR-BI mediated the uptake of vitamins as well as viral entry 
into cells [17]. Recently, SR-BI has also been identified as a potential marker for cancer diagnosis 
and prognosis [17]. It was reported that abnormal expression of SR-BI may have been associated 
with tumorigenesis and malignant transformation [18-20]. For example, several patient tumors 
display higher expression of SR-BI compared to healthy tissue, including adrenal tumors, breast 
cancer, prostate cancer, lymphoma, nasopharyngeal carcinoma, pancreatic cancer, prostate 
bone metastasis, and testicular cancer [18-20]. SR-BI could also serve as a promising target for 
the delivery of therapeutic agents by reconstituted HDL, which directly binds to the SR-BI protein 
on plasma membrane [19, 20]. 
 
Natural products are a promising source for the discovery of new drug leads [21]. Some natural 
products, including such from plants, fungi and marine sources, are reported to regulate SR-BI 
protein expression (reviewed in [22]). It was reported that only about 6% of the existing higher 
plants have been investigated pharmacologically, highlighting that there is still a lot of unexplored 
potential [23]. In our review, we discuss the relationship between SR-BI protein and cancer, and 
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the molecular mechanism regulating SR-BI expression, as well as provide an overview of natural 
products that regulate SR-BI expression. 
 
2. SR-BI functions 
 
2.1 General function  
 
Hepatic SR-BI mediates selective HDL-CE uptake from peripheral tissues and the transhepatic 
transport of HDL cholesterol into bile regulates the reverse cholesterol transport (RCT) [24-26]. 
SR-BI is a multifunctional receptor, with recent studies demonstrating that SR-BI affects 
gastrointestinal, endocrine, reproductive, and cardiovascular pathophysiology [27-32]. SR-BI is 
involved in both cholesterol uptake and efflux in cells (Figure 1) [33, 34] and has been shown to 
be the key gatekeeper for specific delivery of cholesterol in human steroidogenic cells [35]. SR-
BI promoted the production of glucocorticoids and modulated inflammatory response to protect 
from endotoxemia and septic death [36, 37]. Along the same line, human patients with SR-BI 
P297S had a remarkable decrease in urinary steroid secretion, an impaired response to 
corticotropin stimulation [38, 39], and symptoms resembled with impaired adrenal function. These 
observations suggest that SR-BI was critical for adrenal steroid synthesis. In addition, SR-BI was 
shown to be involved in improving inflammation, limiting cell death and regulating efferocytosis of 
apoptotic cells [2]. In this context, there was increased oxidative stress in SR-BI knockout (KO) 
mice with dysfunctional HDL [40, 41]. SR-BI increased the protein expression of endothelial nitric 
oxide synthase (eNOS) in endothelial cells through Akt (also known as protein kinase B (PKB)) 
and mitogen-activated protein kinase (MAPK) signaling pathway [42-44]. In addition, recent 
studies demonstrated that SR-BI was responsible for red blood cell maturation, lymphocyte 
homeostasis, and deficiency of SR-BI resulted in systemic autoimmune disorders by modulating 
the proliferation of lymphocytes as well as the cytokine production by lymphocytes and 
macrophages in mice [45-47]. SR-BI also modulated platelet cholesterol contents, platelet activity 
and thrombosis in dyslipidemia [48, 49]. SR-BI deficient macrophages were defective in 
autophagy following stress [50], and impaired autophagy, promoted atherosclerosis [51]. 
Therefore, SR-BI is a receptor with pleiotropic functions and may affect cell functions by mediating 
the bi-directional flux and net movement of cellular free cholesterol [50]. Future studies need to 
establish the mechanisms by which SR-BI regulates autophagy in human macrophages, and 
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whether its role is associated with CE mobilization, macrophage apoptosis and the chronic 
inflammatory diseases. 
 
Macrophages from patients with loss-of-function SR-BI variants had impaired ability to promote 
cholesterol efflux [38, 39], suggesting that macrophage SR-BI played an important role in 
cholesterol homeostasis and chronic inflammatory diseases [52]. Recent epidemiologic studies 
demonstrated that there was a significant inverse relationship between HDL-cholesterol (HDL-C) 
levels, HDL particle numbers and risk of cancer development and prognosis [53-56]. Up to now, 
there are several SR-BI variants identified from human subjects with abnormal HDL-C levels 
(Table 1). Two missense mutations S112F (Serine to Phenylalanine), T175A (Threonine to 
Alanine) were associated with 37% increased HDL-C in heterozygotes, and P297S (Proline to 
Serine) was associated with increased HDL-C and reduced cholesterol efflux capacity. It has been 
shown that a coding variant of SR-BI I179N (Isoleucine to Asparagine) remarkably promoted 
atherosclerosis in mice [57]. It is worth to note that the new variant P376L (Proline to Leucine) 
resulted in the complete loss of function, which led to high HDL-C phenotype in human [58]. The 
heterozygotes had a 2.8-fold increase and the homozygotes had a 6.1-fold increase in large HDL2 
particles compared with noncarrier control. The further characterizations of these point mutations 
of SR-BI, including cell surface expression, binding activity to HDL, and SR-BI signaling pathway 
were intriguing. The binding ability of SR-BI P376L to HDL was almost completely abolished and 
the binding ability of P297S to HDL was decreased to half of SR-BI wild type (WT).  More 
importantly, P376L mutation of SCARB1 was associated with increased risk of coronary heart 
disease (CHD) [58, 59]. However, three rare SR-BI mutations identified from human patients 
(G319V, V111M, and V32M) were associated with elevated levels of HDL-C, but not with coronary 
artery disease (CAD) [60]. It remains to be addressed whether there is causal relationship 
between loss of function mutations of SR-BI and tumor progression. 
 
2.2 SR-BI and cancer 
 
2.2.1 SR-BI and cholesterol metabolism in cancer  
 
Changes in cholesterol metabolism resulted in the alteration of intratumoral synthesis of 
androgens in castration-resistant prostate cancer [61]. Cytochrome P450 (CYP) 27A1, also 
known as sterol 27-hydroxylase, is an important enzyme in both the acidic and neutral pathways 
of bile acid and cholesterol metabolism [62]. CYP27A1 oxidizes the terminal carbon of the 
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cholesterol isooctyl side-chain to an alcohol and subsequently to an acid introducing R 
stereochemistry at C-25 [63]. Given its key role in bile acid biosynthesis and cholesterol 
metabolism, CYP27A1 dysregulation results in dysfunction of cholesterol metabolism and disease 
in humans [64]. It has been shown that CYP27A1 is significantly down-regulated in human 
prostate cancer. Restoring CYP27A1 expression in cells reduced tumor growth in vitro and in vivo 
model with tumor xenografts [65]. Blocking CYP27A1, which encodes enzyme required for 27-
hydroxycholesterol biosynthesis, remarkably prevented metastasis in relevant animal models of 
cancer, while the cholesterol metabolite 27-hydroxycholesterol promoted breast cancer 
metastasis through activation of neutrophils [66], which overall points out that cholesterol 
metabolism plays important roles in cancer development and metastasis. Although there is no 
study examining the specific mechanisms implying SR-BI in development of cancer [67], it has 
been demonstrated that cancer cells can take up CE via HDL/SR-BI pathway and use it as the 
substrate to enhance malignant phenotypes [68, 69]. For example, SR-BI was required for uptake 
of CE from HDL3 in the breast cancer cell line HBL-100 [70]. SR-BI was also needed for selective 
CE uptake providing cholesterol as precursor for production of steroid hormones and for storage 
in intracellular CE droplets of Leydig cells from rat testis [71]. HDL also inhibited the activation of 
sterol regulatory element-binding protein-1 (SREBP-1), which resulted in the transcription of β-
Hydroxy β-methylglutaryl-CoA (HMG-CoA) reductase, a key enzyme of cholesterol biosynthesis. 
It would be intriguing to determine the effect of SR-BI modulation on SREBP-1 activation and 
cholesterol metabolism for steroid hormones (e.g., androgens and estrogens) in relevant cancers, 
such as breast cancer and prostate cancer. 
 
2.2.2 The effect of SR-BI on tumor development 
 
Recent studies demonstrated that the protein expression level of SR-BI was correlated with 
aggressiveness and poor survival in breast and prostate cancer [72]. SR-BI protein expression 
was shown to be remarkably increased in malignant tissues compared to surrounding disease-
free tissues in breast cancer [73], while low SR-BI expression was associated with gastric 
adenocarcinoma tumor aggressiveness [74]. There was abundant expression of SR-BI in 
malignant human epithelial cells and hepatoma cells [73, 75, 76]. SR-BI expression was also 
increased in Leydig cell tumors, prostate cancers, colorectal cancer, ovarian cancer and 
pancreatic cancer [70, 77]. Specifically, SR-BI promoted the proliferation of the breast cancer cell 
line MCF-7 through the phosphoinositide 3-kinase (PI3K)/activator protein-1 (AP-1) signaling 
pathway [68, 78]. Along the same line, overexpression of SR-BI protected breast cancer MCF-7 
9 
cells against tumor necrosis factor (TNF)-α-induced apoptosis, whereas expression of the ECD 
of SR-BI remarkably prevented the cell proliferation [78]. Abolishing SR-BI reduced prostate 
specific antigen (PSA) secretion and viability of prostate cancer cells [79]. Pharmacological 
inhibition of SR-BI reduced breast cancer cell proliferation, prevented tumor growth in xenograft 
tumor mice by inhibition of angiogenesis and Akt activation [68, 69]. In addition, SR-BI was 
involved in the melanoma pigmentation pathway, and deficiency of SR-BI decreased the 
melanocyte master regulator microphthalmia-associated transcription factor (MITF) and inhibited 
extracellular vesicle release in human melanoma [80]. Taken together, SR-BI plays an important 
role in cancer cell proliferation and apoptosis, thus, has a potential major impact in carcinogenesis 
and metastasis.  
 
2.2.3 PDZK1 and SR-BI in cancer  
 
The SR-BI scaffold protein PDZK1 is critical for the cell surface expression of SR-BI  [81]. KO of 
PDZK1 resulted in a post-transcriptional, tissue-specific reduction in SR-BI protein level, and there 
was an increase in plasma total HDL-C and the size of HDL particles in PDZK1 deficient mice, 
which exhibited the similar phenotypes to those observed in SR-BI KO mice [82]. PDZK1 belongs 
to the estrogen-regulated genes expressed in hormone-responsive breast cancer [83]. Recent 
study demonstrated that PDZK1 promoted estrogen receptor (ER)-α-mediated growth of breast 
cancer, indirectly regulated by insulin-like growth factor-1 receptor (IGF-1R), therefore identifying 
a new oncogenic role of PDZK1 in breast cancer [84]. Furthermore, knockdown of PDZK1 
abolished ER-dependent cell growth and decreased c-Myc expression in MCF-7 cells, whereas 
overexpression of PDZK1 promoted cell proliferation through c-Myc. Previous studies 
demonstrated that expression of breast cancer resistance protein (BCRP, gene symbol ABCG2), 
an ATP-binding cassette (ABC) efflux transporter, was reduced in PDZK1 KO mice [85]. PDZK1 
was highly overexpressed in ER-positive breast cancers as compared with ER-negative breast 
cancers, which probably affected SR-BI function and cancer development. However, whether the 
effect of PDZK1 on the growth of cancer cells is dependent on SR-BI needs to be further studied. 
Further studies need to address whether co-transfected cells with PDZK1 and SR-BI mutants 
affects cancer cell surface expression of SR-BI mutants (e.g., P297S, P376L) to regulate cancer 
cell cholesterol metabolism and cell proliferation. 
 
2.2.4 Effects of SR-BI on macrophage polarization and cholesterol efflux in 
tumor-associated macrophages (TAMs) and tumor progression 
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Mounting evidence supported that TAMs were associated with tumor progression, invasion and 
metastasis, and poor prognosis [86]. At the initial stage of tumor development, TAMs were 
observed to exhibit a pro-inflammatory gene profile, which is distinct from that of naive resident 
macrophages. However, TAMs rapidly took on a substitute phenotype with tumor promoting 
immunosuppressive function within the tumor microenvironment [87, 88], although there was a 
specific subsets of macrophages with intrinsic tumoricidal activity [86]. In established tumors, 
TAMs were observed to display a phenotype similar to resident macrophages, which indicated a 
dynamic reprogramming of TAM phenotype during tumor progression. Recent study has shown 
that SR-BI deficiency promoted pro-inflammatory macrophage phenotype and upregulated pro-
inflammatory gene expression. SR-BI KO macrophages promoted the M1 phenotype and failed 
to exhibit an M2 phenotype. Furthermore, SR-BI deficiency promoted activation of ERK1/2 MAPK 
signaling in macrophages stimulated with LPS [89]. These studies demonstrate SR-BI regulates 
macrophage phenotype switching and cholesterol metabolism. Recent studies have shown that 
an unexpected influence for membrane-cholesterol efflux resulted in driving TAM-regulated 
tumorigenesis (Figure 2) [90]. Interestingly, KO of ABCA1/G1 restored the tumor-promoting 
functions of TAMs. Ovarian cancer cell-derived hyaluronic acid (HA) remarkably increased 
membrane cholesterol efflux of TAMs [90], which was associated with increased interleukin (IL)-
4-mediated signaling pathway and inhibition of interferon (IFN)γ-induced gene expression, 
leading to transcriptional and functional reprogramming of TAMs. Specifically, reduction of 
membrane cholesterol in macrophages promoted PI3K activity and mammalian target of 
rapamycin complex (mTORC)2-mediated Akt phosphorylation. PI3K was recently shown to be an 
essential pathway to preserve the pro-tumor functions of TAMs [91], and mTORC2 have been 
associated with IL-4-regulated macrophage activation in different contexts [92-94]. The possible 
mechanistic scenario is that cholesterol-rich membrane micro-domains are required to recruit 
negative mediators of PI3K activity, such as the lipid phosphatase - the SH-2 containing inositol-
5'-polyphosphatase-1 (SHIP-1). SHIP-1 may reside in detergent resistant membrane fractions 
[95], and it is known to inhibit IL-4 signaling in macrophages [93]. However, it remains to be 
determined whether SR-BI contributes to membrane cholesterol efflux in TAMs and whether 
reprogramming of TAMs affects tumorigenesis through SR-BI. This will be an important area of 
investigation, that might provide exciting new insights into the lipoprotein metabolism, tumor 
associated macrophages and tumor progression as well. Taken together, SR-BI is critical for 
regulating the cholesterol homeostasis and inflammatory response. Identification of the detailed 
mechanism by which SR-BI functions, including its adaptor proteins, signaling molecules, and 
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transcriptional regulators, will lay a solid foundation for potential discovery of novel diagnostic or 
therapeutic approaches for cancer. 
 
3. Mechanisms of SR-BI expression regulation 
 
The SR-BI expression can be regulated by transcriptional factors, other endogenous factors, 
noncoding RNAs (ncRNA), as well as its accessory proteins at transcriptional, post-transcriptional, 
or post-translational levels (Table 2 and Figure 3). 
 
3.1 Transcriptional factors 
 
SR-BI is regulated by many transcriptional factors, such as the liver X receptor (LXR), peroxisome 
proliferator-activated receptor (PPAR), farnesoid X receptor (FXR), retinoid X receptor (RXR), 
SREBP, ER, steroidogenic factor-1 (SF-1), hepatic nuclear factor 4α (HNF4α), liver receptor 
homolog-1 (LRH-1), prolactin regulatory element-binding protein (PREB), forkhead box protein O 
(FoxO), dosage-sensitive sex adrenal hypoplasia congenital critical region on the X chromosome, 
gene-1 (DAX-1), Yin Yang-1 (YY-1), pregnane X receptor (PXR), and signal transducer and 




The LXRα and β form heterodimers with the RXR for transcriptional activity [96]. Oxysterol-
activated LXRα/RXR and LXRβ/RXR induced SR-BI transcription in human and murine hepatoma 
cell lines, and in 3T3-L1 preadipocytes by binding to putative LXR response element (LXRE) in 
the promoter region to induce SR-BI-promoter activity, independently of SREBP-1 [97]. On the 
contrary, LXR reduced levels of SR-BI in Caco-2/TC7 cells via a post-transcriptional mechanism 
that involves microRNAs (miR) [98]. In vivo it was demonstrated that treating normolipidemic 
hamsters with LXR agonist GW3965 did not effectively induce the mRNA and protein levels of 
SR-BI in the liver [99]. Furthermore, another animal study indicated that LXR activation by its 
ligand TO901317 reduced SR-BI protein, but not mRNA levels in hepatic membranes of C57Bl/6J 
mice, which is not due to changing PDZK1 [100]. The contradictory observed effects of LXR on 





The PPARα can form heterodimers with the RXR to regulate gene expression [101]. PPARα/RXR 
increased the activity of the SR-BI promoter in the human bladder HTB-9 cells, human 
promyelocytic leukemia HL-60 cells, and human monocytic leukemia THP-1 cells by binding to a 
PPAR response element (PPRE) in the SR-BI promoter [102]. The PPARα specific ligand 
WY14643 increased SR-BI level in the rat hepatocytes and HepG2 hepatoma cells, as well as 
liver endothelial cells [103]. The influence of PPARα on hepatic SR-BI expression in animal 
studies is controversial. In hamsters, dietary polyunsaturated fatty acids (PUFA, a strong inducer 
of PPARα) for 6 weeks, up-regulated hepatic SR-BI mRNA and protein levels [104]. SR-BI 
expression was also increased in atherosclerotic lesions of apolipoprotein (apo)E-deficient mice 
treated with the PPARα ligand Wy14643 [105]. On the contrary, treatment with fibrate, a potent 
PPARα agonist, suppressed SR-BI protein expression in the liver without changing steady state 
of mRNA in both wild-type C57BL/6 mice [106] and PDZK1-deficient mice [107], which may be 
due to down-regulation of Clamp, a putative SR-BI-stabilizing protein found in the hepatic plasma 
membrane, but independent of PDZK1. Moreover, fenofibrate-decreased SR-BI stability was also 
independent of the proteasome, calpain protease, or the lysosome [107]. It remains to further 
identify the precise mechanisms regulating hepatic SR-BI by PPARα. Noteworthy, in human, SR-
BI mRNA level in circulating mononuclear cells was not changed by fenofibrate [108].  
 
A selective PPARγ agonists induced SR-BI expression in rat hepatocytes, endothelial cells, Hepa 
1c1c-7 and Kupffer cells by a mechanism involving co-activation of HNF4α [103]. In addition, the 
PPARγ agonist thiazolidinediones increased hepatic SR-BI mRNA and protein levels in HepG2 
by binding to the SR-BI promoter region to induce SR-BI promoter activity [109]. In vivo, the 
PPARγ agonist GW7845 (20 mg/kg/day) significantly increased SR-BI protein expression in 
adipose tissue, but not liver of C57BL/6 mice [110]. SR-BI expression was also increased in 




The regulation of SR-BI expression by FXR is contradictory. On the one hand, bile acid 
(chenodeoxycholic acid)-activated FXR/RXR suppressed SR-BI expression in hepatocytes by 
inducing the expression of the Small Heterodimer Partner (NR0B2, SHP), which inhibited LRH-1-
transactivation of SR-BI [111]. It was assumed that chenodeoxycholic acid influenced SR-BI 
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possibly through multiple pathways, since it also activated other gene expression regulatory 
pathways besides selective agonism of FXR [112, 113]. A specific FXR agonist GW4064 also 
down-regulated the expression of SR-BI protein in Huh7.5 cells [114]. On the other hand, it was 
reported that GW4064 induced mRNA and protein levels of hepatic SR-BI in vitro and in vivo by 
increasing HNF4α protein expression, which directly targeted HNF4α response elements in the 
SR-BI promoter [115]. Similarly, an FXR agonist obeticholic acid increased hepatic SR-BI mRNA 
and protein levels in hyperlipidemic hamsters, but not in normolipidemic hamsters [116]. FXR can 
directly bind to the intronic inverse repeat separated by one nucleotide (IR1), a FXR response 
element (FXRE), in the mouse SR-BI promoter to increase its expression [117]. In human HepG2, 
FXR can bind to a directed repeat DNA motif DR8 to up-regulate SR-BI expression [118]. In 
addition, in the FXR-deficient mouse model SR-BI expression was significantly decreased [119].  
 
Recently, it was demonstrated that FXR and LXR bound to their recognition sequences within the 
intronic region (containing FXRE (IR-1) and LXRE) of the SR-BI gene and transactivated the 
SR-BI reporter gene in a synergistic manner [99]. In in vivo model, combined treatment of FXR 
and LXR agonists significantly increased the mRNA and protein levels of SR-BI in the liver, while 
FXR or LXR agonists alone did not have such effect [99]. Although the intronic FXRE and LXRE 
regulatory region was not conserved in the human SR-BI genomic sequence, higher mRNA 
expression level of SR-BI was observed in human primary hepatocytes and HepG2 cells exposed 
to combined treatment of FXR and LXR agonists, compared with individual agonist treatment [99]. 
 
RXR forms heterodimers with the LXRα, LXRβ, PPARα, and FXR for transcriptional regulation of 
SR-BI [97, 102, 111]. The RXR agonist 9-cis retinoic acid induced the expression of SR-BI mRNA 




SREBP-1a is a key protein in the transcriptional regulation of some genes by sterols [121]. 
SREBP-1a activated transcription of rat SR-BI by binding to sterol response elements (SRE) in 
the promoter of SR-BI in response to altered intracellular sterol levels [121]. SREBP-1a requires 
the presence of a coactivator like simian-virus-40-protein-1 (Sp1) to promote maximum activation 
of the SR-BI promoter [122]. SREBP-1a is also a potential coactivator of the estrogen-ER-
dependent upregulation of SR-BI gene [123]. 
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SREBP-2 increased SR-BI mRNA and protein levels in transfected HEK293 and HepG2 cells by 
binding to SR-BI promoter [124]. This study also suggests that SREBP-2 is a more potent inducer 
for SR-BI promoter activity than the SREBP-1a isoform in the studied models [124]. On the 
contrary, in SREBP-1a and -1c transgenic mice on normal chow, hepatic SR-BI was 




Estradiol (E2) significantly increased SR-BI promoter activity by activation of ER-α and -β and 
following binding to ER element (ERE) 1, 2, and 4 in vitro [123]. Along with ERs, mixed-lineage 
leukemia (MLL) histone methylases, including MLL1 and MLL2, play important roles in E2-
mediated SR-BI activation, through binding to SR-BI promoter and further control of the assembly 
of transcription pre-initiation complex and RNA polymerase II recruitment [126]. MLL2 knockdown 
in mice reduced SR-BI expression in mouse liver [126]. In addition, high-dose estrogen treatment, 
however, dramatically reduced SR-BI in the liver and increased SR-BI expression in the adrenal 
gland and corpus luteal cells of the ovary in rats [127]. Further study indicated that in the rat liver 
the decrease in SR-BI by 17α-ethinyl estradiol treatment was due to the estrogen-increased low-
density lipoprotein receptor (LDLR) activity, while in the adrenal glands the increase in SR-BI was 
due to inhibition of adrenocorticotropic hormone (ACTH) production [128]. Recently, it was 
reported that estrogen caused down-regulation of endothelial SR-BI in human coronary artery 
endothelial cells depending on G-protein-coupled ER (GPER), but there was no effect on SR-BI 
expression in liver cells because of low expression of GPER in hepatocytes [129]. The estrogen 




SF-1, an orphan member of the nuclear hormone receptor gene family, plays a key role in the 
regulation of steroidogenesis [131]. SF-1 was shown to directly bind to the SR-BI promoter in a 
sequence-specific manner [131], and activated transcription of the SR-BI gene in both human 
HTB9 bladder carcinoma and mouse Y-1 tumor cells, which effect was enhanced by cyclic AMP 
(cAMP) by increasing phosphorylation of SF-1 at Ser 430 by PKA [132]. Furthermore, no SR-BI 
mRNA was detected in the gonadal ridge of day 11.5 SF-1 KO embryos, suggesting SF-1 also 





In cultured hepatocytes, HNF4α increased SR-BI expression at both mRNA and protein levels, 
which can be inhibited by a PPARγ antagonist BADGE [134]. In vivo, hepatic overexpression of 
HNF4α upregulated SR-BI mRNA and protein levels in rat liver possibly by the upregulation of 




LRH-1 induced SR-BI expression by binding to an LRH-1 response element in the promoter of 
SR-BI, which associated with histone H3 acetylation on the SR-BI promoter in vitro [135]. In vivo, 
the SR-BI mRNA levels were decreased in the livers of the heterozygous LRH-1-KO mice [135]. 
LRH-1 was also involved in FXR/RXR-suppressed SR-BI expression by bile acid 




PREB is a transcription factor that regulates prolactin promoter activity in the rat anterior pituitary 
[136]. Overexpression of PREB using a PREB-expressing adenovirus increased the expression 
of the SR-BI protein in the adrenocortical cell line Y-1 cells by binding to the PREB-responsive 
cis-element in the SR-BI promoter under conditions that increase cellular cAMP levels [137]. 
 
3.1.10 FoxO  
 
Recently, it was reported that mice with liver-specific triple FoxO KO (FoxO1,3,4) had substantially 
decreased hepatic SR-BI expression [138]. In our experiments, knockdown of FoxO1 did not 




The nuclear receptor NR0B1 (DAX-1) plays an important role in adrenal development [6]. DAX-1 
repressed activation of the SR-BI promoter not only through interaction with SREBP-1a to prevent 
subsequent binding of SREBP-1a to SR-BI promoter, but also by formation of a complex with SF-
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1 protein on the DNA to prevent activation of SR-BI promoter in transfected adrenal Y-1, HTB-9, 




The ubiquitous zinc finger transcription factor YY-1 has been shown to repress several sterol-
responsive gene promoters [140]. YY-1 also repressed the activity of the SR-BI promoter, and 
attenuated the transcriptional synergy caused by the combined actions of SREBP-1a and a co-
activator like simian-virus-40-protein-1 (Sp1) by inhibiting the binding of SREBP-1a to SR-BI 




SR-BI was inhibited by the PXR activators rifampicin and lithocholic acid in HepG2 cells, as well 
as by pregnenolone 16α-carbonitrile (PCN) in primary rat hepatocytes [142]. In vivo study 





The mutagenesis of a STAT1/STAT2 response element in the SR-BI promoter abolished the 
ability of IFNα to suppress SR-BI promoter activity [144]. 
 




In steroidogenic cells, the expression of SR-BI is regulated by trophic hormones in concert with 
the regulation of steroid hormone production [145]. The protein and mRNA expression of SR-BI 
were increased in cultured murine Y1-BS1 adrenal cells treated with ACTH [146]. ACTH-
stimulation of SR-BI can be mediated through cAMP-increased binding of SF-1 to the SR-BI 
promoter [17]. It was reported that in vivo ACTH treatment increased SR-BI protein expression in 
adrenal glands of C57BL/6 mice, which was suppressed by treatment with the glucocorticoid 
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dexamethasone phosphate [147]. In addition, in the acute phase of adrenocortical 
steroidogenesis, ACTH rapidly stimulated the metabolism of sphingolipids and the secretion of 
sphingosine-1-phosphate (S1P), which further increased the expression of SR-BI [148]. ACTH 
treatment can modulate SR-BI expression at the transcriptional and posttranscriptional levels, 
and the underlying mechanisms were recently summarized by Shen et al. [149].  
 
Glucocorticoids suppressed SR-BI expression in adrenocortical H295R and ovarian SKOV-3 cells 
depending on the glucocorticoid receptor (GR), which cannot directly bind to the SR-BI promoter 
[150]. Further study showed that glucocorticoids repressed SR-BI expression through the region 
between nucleotides -201 and -62 in the human SR-BI promoter, which included putative binding 
sites for transcriptional repressors for SR-BI gene transcription [150]. In vivo, SR-BI mRNA level 
was upregulated in adrenals of corticosterone-deficient mice, whereas corticosterone treatment 
inhibited SR-BI gene expression in these mice [150]. Treatment with metyrapone, an inhibitor of 
corticosterone synthesis, increased SR-BI mRNA level in adrenals from wild-type mice [150]. On 
the contrary, the glucocorticoid dexamethasone increased SR-BI mRNA expression in primary rat 
hepatocytes, which was reduced by the addition of the anti-glucocorticoid mifepristone [151]. The 
stimulation effect of dexamethasone was not observed in HepG2 cells and THP-1 macrophages 
[151]. 
 
Angiotensin II (Ang II) was reported to suppress SR-BI expression in human umbilical vein 
endothelial cells by PI3K/Akt/FoxO1 pathway by downregulating SR-BI promoter activity, which 
was rescued by the Ang II receptor type 1 (AT1) blocker olmesartan [152]. Ang II treatment also 
down-regulated SR-BI protein and mRNA expression in a mouse proximal tubular cell line MCT 
cells, which effect was attenuated by an AT1 antagonist, but not an AT2 antagonist [153]. In vivo, 
Ang II-infusion into rats induced a significant decrease of SR-BI protein expression in isolated 
tubules [153]. On the contrary, in the human adrenocortical carcinoma cell line NCI-H295R cells 
Ang II stimulated SR-BI mRNA and protein expression by activation of the human SR-BI promoter 
[154]. 
 
Insulin increased both mRNA and protein levels of SR-BI in polarized CaCo-2 cells, which effects 
were abrogated by PI3K, Akt, or mTOR pharmacological antagonism [155]. In vivo, SR-BI 
expression was increased in all intestinal segments in two diet-induced animal models of insulin 
resistance (fructose-fed hamster and high-fat-fed mouse) [156]. It was reported that IGF-1 
decreased SR-BI mRNA and protein levels by the PI3K/Akt signaling pathway in THP-1-derived 
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macrophages [157]. Similarly, IGF-1 suppressed expression of SR-BI in cultured HepG2 cells 
[158]. Consistent with in vitro data, in rats infused with IGF-I for 7 days SR-BI mRNA level was 
decreased [158]. The PI3K/Akt pathway participated in IGF-1-inhibited SR-BI expression by 
suppression of activity of the human SR-BI promoter [158]. Pregnancy-associated plasma protein-
A (PAPP-A)-decreased SR-BI expression in THP-1 macrophage-derived foam cells was 
mediated through the IGF-1/PI3K/Akt signaling pathway [158]. In vivo, PAPP-A knockdown by 
PAPP-A shRNA in apoE-deficient mice reduced the IGF-1 levels, repressed the PI3K/Akt pathway, 
and in turn increased SR-BI expression in both aorta and peritoneal macrophages [159]. 
 
It was also reported that thyroid hormone receptor β (TRβ), hepatic lipase (HL), testosterone and 
leptin also can regulate SR-BI expression. Activation of TRβ by its agonist GC-1 increased SR-
BI expression [160]. Inhibition of HL in mice up-regulated the SR-BI expression in adrenal gland 
[161, 162]. Testosterone up-regulated SR-BI mRNA and protein levels in both cultivated HepG2 
cells and primary human monocyte-derived macrophages (HMDMs) [163]. In leptin-deficient mice, 
the hepatic SR-BI protein level was reduced [164]. Treatment with leptin for 2 days dose-
dependently increased hepatic SR-BI protein and mRNA levels in leptin-deficient mice [164]. 
 
A recent study suggested that DNA methylation may participate in hormonal regulation of SR-BI 
expression in a tissue-specific manner [145]. The SR-BI gene contains one CG island (CGI) in its 
promoter and seven CGIs in its intronic regions [145]. It was demonstrated that the seven intron 
CGIs were methylated differentially in mouse adrenal Y-1 cells, mouse Leydig tumor cells 
(MLTCs), ovarian granulosa cells, and mouse liver Hepa 1-6 cells through N(6), 2'-O-
dibutyryladenosine3':5'-cyclic monophosphate regulation [145]. In addition, DNA 
hypermethylation of the SR-BI promoter in rat fetal adrenal glands may lead to decreased SR-BI 
expression [165]. 
 
3.2.2 Other endogenous factors 
 
The cytokine IFNα suppressed SR-BI expression in HepG2 cells by a pathway involving 
phosphorylation of STAT1/STAT2, which in turn bound to STAT1/STAT2 response element in the 
SR-BI promoter to inhibit SR-BI promoter activity [144]. The second messenger cAMP increased 
SR-BI mRNA expression in transfected 293T cells, human granulosa SVOG-4o cells, and in 
primary cultures of rat theca-interstitial cells by the cAMP response element binding protein 
(CREB), which directly bound to promoter of SR-BI to induce its activation [166].  
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It was shown that administration of liver growth factor (LGF) to ethane dimethanesulfonate (EDS)-
treated rats resulted in a remarkable increase in the levels of SR-BI protein [167]. Hormone-
sensitive lipase (HSL) KO male mice have increased SR-BI protein expression, but not mRNA 
levels in the testis [168]. The molecular mechanisms by which LGF and HSL regulated SR-BI 
expression remain to be further studied. 
 
It was shown that high glucose (25-30 mM) decreased SR-BI mRNA and protein levels in HMDMs 
[169], Caco-2/15 cells [170], and HepG2 cells [171]. Further study indicated that glucose-induced 
suppression of hepatic SR-BI expression was partially mediated by the activation of the p38 
MAPK-specificity protein-1 pathway [171]. In vivo, hepatic expression of SR-BI was lower in 
diabetic rats than in euglycemic rats [171]. On the other side, in J774A.1 macrophage-like cells, 
high glucose (30 mM) increased SR-BI mRNA and protein expression [172]. Furthermore, SR-BI 
mRNA and protein expression were significantly increased in mouse peritoneal macrophages 
(MPM) harvested from C57Bl/6 diabetic mice, compared to MPM from control non-diabetic mice 
[172]. In addition, one study showed that high glucose (25 mM) did not modify SR-BI abundance 




Recently, ncRNA, such as miRs have been investigated in the regulation of SR-BI expression. 
MiRs regulate SR-BI expression at the post-transcriptional level by directly binding to 
complementary sequences in the 3’-untranslated regions (3’-UTR) of SR-BI mRNA, causing RNA 
destabilization or translational repression. The miRs regulating SB-BI expression include miR-24, 
miR-96, miR-125a, miR-185, miR-217, miR-223, and miR-455.  
 
Recent work demonstrated that miR-24 inhibited SR-BI protein expression in HepG2 and THP-1 
cells by specifically targeting the 3’-UTR of SR-BI mRNA [173]. Another group also indicated that 
miR-24 decreased SR-BI level in steroidogenic cells MLTC and Y-1, as well as HepG2 cells [174]. 
In vivo, miR-24 administration decreased hepatic SR-BI expression and promoted atheromatous 
plaque formation in apoE-deficient mice [173]. It was shown that the level of SR-BI expression 
was repressed by miR-96, miR-185, and miR-223 in HepG2 cells, which directly targeted the 3’-
UTR of SR-BI mRNA with a coordinated effect [175]. Furthermore, the decrease of miR-185 and 
miR-96 is related to the increase of SR-BI in the liver of apoE-deficient mice exposed to a high fat 
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diet (HFD) [175]. Another study found that miR-125a and miR-455 negatively regulated mRNA 
and protein levels of SR-BI in the rat Leydig tumor R2C cells and the cAMP-sensitive cells MLTCs 
[176]. Further study showed that miR-125a, but not miR-455 inhibited expression of hepatic SR-
BI in the mouse and rat livers as well as the mouse hepatic cell line Hepa 1-6 [176]. It was reported 
that miR-217 mimic administration in apoE-deficient mice significantly down-regulated SR-BI 
mRNA levels [177]. The mechanisms of miR-217-mediated regulation of SR-BI are not yet clear. 
Moreover, other miRs regulating the SR-BI expression remain to be further explored. 
 
3.4 Accessory proteins interacting with SR-BI protein 
 
Accessory proteins, PDZK1/Na+/H+ exchanger regulatory factor 3 (NHERF3), NHERF1 and 
NHERF2, can interact with SR-BI, which in turn can regulate the expression of SR-BI at the post-
translational level [17]. PDZK1 is expressed in liver, kidney and gut, but not in steroidogenic 
tissues [112], whereas NHERF1 and NHERF2 are expressed in steroidogenic cells of the adrenal 
gland, ovary and testis, as well as the liver [17, 178]. All NHERFs contain multiple “PDZ” domains 
(postsynaptic density (PSD-95), Drosophila disc large tumor suppressor (Dlg-1), and zona 
occludense-1 protein (ZO-1)) [6, 179], which bind and interact with the PDZ recognition motif in 
SR-BI to regulate its protein stability [180, 181]. It was reported that SR-BI protein expression in 
PDZK1-deficient mice was reduced by 95% in the liver, 50% in the proximal intestine, but not 
affected in steroidogenic organs [178]. On the contrary, NHERF1 and NHERF2 overexpression 
down-regulated the SR-BI protein expression in liver and steroidogenic tissues/cells [180]. The 
regulation exerted by NHERFs on SR-BI expression was summarized by several reviews [6, 17, 
112]. The nuclear receptors LXRα- and PXR-regulatory action on SR-BI could also be through 
affecting PDZK1. One study indicated that activation of LXRα enhanced mRNA expression of 
PDZK1 in HepG2 cells, while activation of PXR reduced the protein amount of PDZK1 [182]. 
 
4. Natural products regulating SR-BI 
 
Natural products have been historically proven to be a promising pool of structures for drug 
discovery [21], and significant efforts have recently been taken to explore the SR-BI regulatory 
potential of natural products originating from traditional medicine or dietary source [183, 184]. 





Polyphenols are the most well-known natural products which possess many bioactivities, 
including regulation of SR-BI expression [185, 186]. This class of phytochemicals is chemically 
characterized by common polyhydroxylated phenolic moieties. They include two main classes: 
flavonoids and non-flavonoids [187, 188]. 
 
4.1.1 Flavonoids 
     
4.1.1.1 Flavonols 
     
Some of the major flavonol compounds are quercetin and kaempferol. Onions, broccoli, apples, 
green tea, and black grapes are the sources of these flavonols. Most research on flavonols related 
to SR-BI expression focused on cellular cholesterol efflux [189]. Quercetin significantly increased 
the expression of SR-BI in HepG2 cells in a concentration- and time-dependent manner [190]. 
Moreover, quercetin induced the expression of SR-BI and the selective uptake of HDL-C through 
PPARγ pathway [190]. Kaempferol, extracted from a classic Chinese medicine Carthami Flos 
which is used for promoting blood circulation and removing blood stasis, up-regulated SR-BI 




The dietary consumption of polyphenols consists principally of 80% flavanols, which mainly 
include catechins and tannins [187, 188]. Treatment with catechins (30 mg/kg) in rats increased 
mRNA expression of SR-BI in aorta and in liver, which resulted in anti-atherogenic properties 
[192]. 1,2,3,4,6-penta-O-galloyl-β-D-glucose (PGG) is a prototypical gallotannin and the key 
compound in the biosynthetic pathway of hydrolysable tannins. It is highly enriched in medicinal 
herbals such as Rhus chinensis, Paeonia lactiflora, and Acer truncatum. PGG increased 
expression of SR-BI in both J774 and THP-1 macrophages [193]. 




Flavones include apigenin, chrysin, diosmin, luteolin and baicalein, which could be detected in 
fruits, nuts, and vegetables [194]. Apigenin-7-O-β-D-glucuronide, which is present in Cirsium 
japonicum DC, was reported to enhance the expression of SR-BI and inhibit the uptake of oxLDL 
by macrophage [195]. Luteolin, a bioactive compound abundant in celery and green bell pepper, 
induced SR-BI expression and further inhibited oxLDL-elicited macrophage foam cell formation 
[196]. 
 
4.1.2 Non flavonoids 
 
4.1.2.1 Phenolic acids 
 
Phenolic acids are widely found in a variety of nuts and fruits, such as raspberries, grapes, 
strawberries, walnuts, cranberries, and black currants. These compounds exist predominantly as 
hydroxycinnamic acids (p-coumaric acid, caffeic acid, ferulic acid, chlorogenic acid, and sinapic 
acids) and hydroxybenzoic acids (gallic acid, salicylic acid, protocatechuic acid, ellagic acid, 
gentisic acid) or alternatively as conjugated forms [197]. Caffeic acid and ferulic acid, the major 
phenolic acids isolated from coffee, were proven to regulate SR-BI expression, and have anti-
atherogenic properties by enhancing HDL-mediated cholesterol efflux from the macrophages 
[198]. Ellagic acid regulated PPARγ-SR-BI signaling pathway and in turn downregulated 





Among stilbenes, resveratrol (3,5,4’-trihydroxy-trans-stilbene) is the well-studied stilbenoid. 
Resveratrol is a natural polyphenolic stilbene found in grape skin, nuts, and some herbal 
medicines, such as Fallopia japonica [200]. Resveratrol is widely used as an anti-cancer, anti-
oxidant and anti-atherosclerosis dietary supplement [201]. Many molecular actions of resveratrol 
rely on the activation of AMP-activated protein kinase (AMPK) and sirtuin 1 (SIRT1) [202]. It has 
been demonstrated to be responsible for the protective effect in different pathological processes 
characterized by hyperlipidemia [203]. In human keratinocytes, resveratrol was able to increase 
SR-BI protein level in a dose-dependent manner [204]. Resveratrol has also been proved to 
decrease serum cholesterol level through induction of major cholesterol transporters (ABCA1, 
ABCG1 and SR-BI) in both human macrophages and endothelium, which in turn stimulated 
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removal of free cholesterol and cholesterol esters [205]. Although positive effects of polyphenols 
have been observed in preclinical studies, it is important to point out that, in humans, most of the 
bioactive effects depend on the absorption and metabolism of these compounds [206-208]. Thus, 
further clinical studies are warranted to determine the bioactivity and biotransformation of 
polyphenols toward regulation of SR-BI expression in humans [209]. 
 
4.1.3 Clinical study 
 
SR-BI plays a very important role in regulation of cholesterol metabolism in humans. Hepatic SR-
B1 mediates the selective uptake of HDL-CE into the liver for excretion in the bile and ultimately 
the faeces to decrease cholesterol level. Thus, most of clinical studies focus on the effect of 
compounds on the levels of total cholesterol, LDL-cholesterol, and HDL-cholesterol. Polyphenols 
were reported to exhibit the beneficial effects on hyperlipidemia while contrary opinions also exist. 
Dietary flavonoids were regarded as related factors of reduced total and LDL cholesterol and 
increased HDL fraction [210-214]. In the Moli-sani cohort, higher intake of polyphenols was 
associated with lower total and LDL cholesterol and higher HDL cholesterol levels [215]. In a 
subset cohort of the ATHENA study, total polyphenol intake was not associated with an improved 
lipid profile, but individuals with the serum paraoxonase/arylesterase 1 single nucleotide 
polymorphisms rs854549 and rs854552 showed a positive association between HDL cholesterol 
levels and total polyphenol intake [216]. A 4-week, double blind, randomized, placebo controlled 
trial involving 32 type 2 diabetes patients showed that flavonoid-rich grape seed extracts 
significantly improved the biomarkers of glycemia and hyperlipidemia [217]. A randomized, 
double-blind, placebo controlled trial with 48 diabetes patients revealed that a 12-week daily 
supplementation of pycnogenol (125 mg), could reduce CVD risk factors (such as lowering 
cholesterol level) [218]. Red wine polyphenols were found to have a beneficial effect on plasma 
concentrations of lipoprotein and cholesterol in a randomized clinical trial involving 67 men with 
high cardiovascular risk [219]. In a randomized, controlled, cross-over study, a single dose of 
flavonoid-rich black tea was found to significantly reduce blood glucose and cholesterol in men 
and women without history of cardiovascular disease (CVD) or diabetes [220]. Another 
randomized controlled trial was launched in subjects with obesity and metabolic syndrome 
following an 8-week supplementation with green tea beverage (928 mg catechins) or 
encapsulated green tea extracts (870 mg catechins). Green tea consumption showed a 
decreasing trend in LDL cholesterol [221, 222]. The blood cholesterol-lowering effects of 
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resveratrol were observed in type 2 diabetes [223], and in obese men with impaired insulin action 
[224]. 
 
On the contrary, a prospective cross-sectional study conducted on 38,018 women suggested 
there was no relationship between flavonols or flavones consumption and the risk of CVD [225]. 
Two randomized, double-blind, placebo controlled trials showed the supplementation of 
polyphenol might not improve cholesterol profile in non-diabetic subjects with impaired glucose 
tolerance [226]. Long-term randomized trials are warranted to reveal the effects of polyphenols in 
humans. 
 
Ongoing and completed clinical trials have reported the safety and efficacy of polyphenols as 
anticancer agents [227]. A phase I study showed the efficacy and safety of muscadine grape skin 
extract (which contains ellagic acid, quercetin, and resveratrol) in men with biochemically 
recurrent prostate cancer [228]. Flavonoids might be specific components that could reduce 
ovarian cancer risk. 171,940 Nurses’ Health Study participants were followed to examine 
associations between intakes of total flavonoids, including their subclasses flavanones, flavonols, 
anthocyanins, flavan-3-ols, flavones, and polymeric flavonoids, and risk of ovarian cancer by 
using Cox proportional hazards models. Participants in the highest quintiles of flavonol and 
flavanone intakes had modestly lower risk of ovarian cancer, especially the association for 
flavanone being stronger for serous invasive and poorly differentiated tumors [229]. Quercetins, 




4.2.1 Purine alkaloids 
 
Purine alkaloids are produced in a variety of plant species, e.g., coffee, tea and cacao. The most 
abundant purine alkaloid is caffeine. Prenatal caffeine ingestion (PCI) induced intrauterine growth 
retardation (IUGR). Further studies indicated that caffeine inhibited SR-BI-mediated cholesterol 
uptake in fetal adrenals, subsequently decreased glucocorticoid synthesis and induced IUGR. 
Moreover, caffeine induced long-term alterations in SR-BI expression and glucocorticoid 
synthesis in adult male offspring rat adrenals [231]. 
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4.2.2 Benzylisoquinoline alkaloids 
 
Benzylisoquinolines are mainly contained in basal angiosperms, e.g., in members of the 
Berberidaceae, Fumariaceae, Papaveraceae, Menispermaceae, and Ranunculaceae [232].  
Berberine is the principal bioactive ingredient of Rhizoma coptidis, a common traditional Chinese 
herb used for the therapy of inflammatory disorders and diabetes mellitus [233]. Berberine up-
regulated SR-BI expression, and inhibited oxLDL-induced foam cell formation from macrophage 
by inhibiting the lectin-like oxidized LDL receptor-1 (LOX-1) [234]. 
 
4.2.3 Trimethylglycine  
 
Trimethylglycine, also called betaine, is a crystalline alkaloid contained in sugar beets and other 
plants. Betaine serves as an animal and human nutrient, which has been well investigated in 
respect of its effects on lipid metabolism and CVD, as well as liver disease [235, 236]. Feeding 
pigs with betaine-supplemented diets during pregnancy and lactation increased hepatic LDLR 
and SR-BI gene expression [237]. Chronic ethanol markedly inhibited the glycosylation of SR-BI, 
resulting in the decreased localization of the mature SR-BI in the liver as well as alcoholic 
hyperlipidemia. Betaine effectively prevented chronic alcohol-mediated impairment of SR-BI 
glycosylation, plasma membrane localization, and consequent impaired cholesterol uptake 
function [238]. 
 
4.2.4 Clinical study 
 
Several systematic reviews and meta-analyses of randomized controlled trials have consistently 
demonstrated the beneficial effects of alkaloids on blood cholesterol [230, 239-241]. To date, a 
number of human trials have been performed on subjects with different disease conditions 
including those with hypercholesterolemia [242-244], metabolic syndrome [245, 246] and CVD 
[247]. Meta-analysis of 11 clinical trials (including 874 participants) have revealed that the 
administration of berberine produced a significant reduction in total cholesterol, triglycerides and 
LDL cholesterol levels, with a remarkable increase in HDL [248]. The majority of the human trials 
showed reductions of 11-29% in total cholesterol and 8-25% in LDL cholesterol while a few did 
not show significant effects [245, 249]. 
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Various human clinical studies have found that in addition to alkaloids’ association with metabolic 
diseases, betaine intake is associated with cancers, such as lung cancer [250] and liver cancer 
[251]. In these studies, a higher betaine intake resulted in a lower risk of cancer. Furthermore, 
research has suggested that cancer incidence could be decreased by 11% by consuming choline 
plus betaine (100 mg/day) [252]. The association between caffeine intake and cancer has been 
extensively studied. Recently in a clinical trial on prostate, lung, colorectal, and ovarian cancer 
screening, of the 97,334 eligible individuals, 10,399 developed cancer. Caffeine intake was not 




Terpenoids are a group of about 40 000 compounds with diverse structures, all sharing the 
characteristic of being synthesized from isoprenoid building blocks. According to the number of 
these isoprene units, Terpenoids of 5, 10, 15, 20, 30 and 40 carbon atoms are classified as hemi-, 
mono-, sesqui-, di-, tri- and tetra-terpenes, respectively [254]. For instance, the sesquiterpenes 
isolated from various species of marine sponges exhibited various biological activities. New 
tetracyclic merosesquiterpenes, including both 19-methoxy-9,15-ene-puupehenol isolated from 
the marine sponge Hyrtios digitatus and the known 20-methoxy-9,15-ene-puupehenol could 
activate SR-BI in HepG2 cells [255]. Tetraterpenoids, also called carotenoids, comprise a group 
of tetraterpenes in plants. β-Carotene, the principal provitamin A carotenoid, partly controlled SR-
BI activity through a feedback regulation [256]. Indeed, studies have pointed out that SR-BI 
activity was partly controlled by cleaved β-carotene retinoids. Using both mouse models and 
human cell lines, it was specifically shown that retinoic acid induced the expression of the 
intestinal transcription factor intestine-specific homeobox (ISX) that repressed the expression of 
SR-BI [257], thus impacting both carotenoid conversion and uptake [258]. To the best of our 
knowledge, there are a large number of in vitro studies demonstrating the cytotoxicity of terpenoid 
molecules against various breast [259], prostate [260] and liver cancer cells [261], yet very few 
compounds have been evaluated in clinical study. 
 
4.4 Unsaturated fatty acid 
 
Omega-3 fatty acids, such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), 
induced higher gene expression of SR-BI, ABCA1, and ABCG5, which might be the mechanisms 
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by which these compounds increased fecal cholesterol excretion from obese hamster compared 
to control [262]. Olive oil, containing oleic acid, up-regulated the genes of SR-BI, ABCA1, PPARγ 
and CD36 [263], which might contribute to the cardiovascular-protective effect of olive oil [263]. 
13-hydroxy linoleic acid (13-HODE), which is the hydroxylated derivative of linoleic acid (LA), is a 
natural PPAR agonist [264]. 13-HODE increased protein levels of SR-BI, LXRα, ABCA1, and 
ABCG1 in macrophages, and further induced macrophage cholesterol efflux [265]. 
 
Dietary guidelines recommended by the American Heart Association (AHA) for health individuals 
include consumption of omega-3 fatty acids [266]. However, the increase in LDL-cholesterol is a 
potential disadvantage of omega-3 fatty acids consumption [267, 268]. On the contrary, the 
COMBOS study revealed a reduction from baseline in non-HDL-cholesterol was significantly 
greater with omega-3 acid ethyl esters (OM-3A EE) plus simvastatin than with simvastatin alone 
[269]. Treatment with OM-3-A EE also significantly reduced TG levels and VLDL-cholesterol 
levels compared with placebo. Many publications indicated the efficacy of omega-3 fatty acids in 
cancer therapy. In an epidemiological study, women affected by metastatic breast cancer 
supplemented with 1.8 g of DHA during chemotherapy with anthracyclines could increase their 
survival by 8 months and decrease symptoms [270].  EPA (2.7 g/day) has been reported to be 
able to inhibit colorectal aberrant crypt foci, compared to placebo control group after one month 
of supplementation in a Japanese clinical trial [271]. Due to low side effects, high efficacy, and 
tolerability against chemotherapy and radiotherapy, a plenty of clinical studies has been 




Guar gum (GG) is a viscous polysaccharide extracted from the seed of the legume plant 
Cyamopsis tetragonolobus that has been reported to have hypocholesterolemic effects in guinea 
pigs [273], rats [274], and humans [275]. In pigs fed with an atherogenic diet, GG consumption 
reduced hepatic SR-BI mRNA to 36% of the control expression but did not affect SR-BI protein 
abundance [276]. β-Glucans comprise a group of β-D-glucose polysaccharides naturally 
localizing in the cell walls of cereals. It was reported that fungi β-glucan from oat fiber remarkably 
increased phagocytosis and SR-BI expression in the macrophage, decreased blood levels of LDL-
cholesterol (LDL-C) and reduced the risk of CVD [277]. 
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It was shown that flavonoids (e.g., luteolin, quercetin, kaempferol), stilbenes (e.g., resveratrol, 
amorphastilbol), and unsaturated fatty acids (e.g., omega-3 fatty acids, oleic acid) can be acting 
as ligands of PPARs, which regulate SR-BI expression as discussion in section 3. It was also 
reported that the natural chenodeoxycholic acid, isolated from goose bile or Calculus bovis, could 





SR-BI is a membrane glycoprotein and expressed in many normal and hormonally altered tissues 
and cell types. SR-BI is critical to lipoprotein metabolism by mediating selective uptake of CE from 
HDL in liver cells and the bi-directional flux of free cholesterol [16]. SR-BI is emerging as a 
multifunctional protein, which regulates clearance of remnant lipoproteins and Lp(a), autophagy, 
efferocytosis, autophagy, apoptosis, inflammation, adrenal steroid synthesis, oxidative stress, 
uptake of vitamins and viral entry into cells [2], as well as affects gastrointestinal, endocrine, 
reproductive, and cardiovascular pathophysiology [27-32]. In addition, SR-BI could also serve as 
a promising target for the delivery of therapeutic agents by reconstituted HDL [19, 20]. There are 
a number of studies trying to understand the relationship between functions of SR-BI and various 
diseases, including cancer and CVD. 
 
It has been demonstrated that cholesterol metabolism was changed in cancer cells [61]. Cancer 
cells can take up CE via HDL/SR-BI pathway and use it as the substrate to enhance malignant 
phenotypes [68, 69]. It was also shown that cholesterol metabolism plays an important role in 
cancer development and metastasis [66]. Furthermore, the protein expression level of SR-BI was 
demonstrated to correlate with development of some cancers, such as breast cancer, gastric 
adenocarcinoma tumor, prostate cancer, colorectal cancer, ovarian cancer and pancreatic 
cancer [70, 72, 77]. It was indicated that SR-BI plays an important role in cancer cell proliferation 
and apoptosis, suggesting its effect on carcinogenesis and metastasis. It was also shown that 
SR-BI regulates proliferation or apoptosis of cancer cells possibly through PI3K/AP-1, Akt or MITF 
pathways. It still remains to further examine the specific mechanisms for SR-BI involvement in 
development of cancer. SR-BI accessory protein PDZK1 is also involved in caner. PDZK1 
regulated cell growth possibly by mediating c-Myc expression, which is often constitutively 
expressed in cancer cells. However, whether the effect of PDZK1 on the growth of cancer cells is 
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dependent on SR-BI needs to be further studied. In addition, TAMs are associated with tumor 
progression, invasion and metastasis, and poor prognosis [86]. TAMs can switch to a phenotype 
promoting immunosuppressive function within the tumor microenvironment [87, 88], which may 
be mediated by SR-BI. The membrane cholesterol efflux of TAMs also influenced TAM-regulated 
tumorigenesis possibly by PI3K activity or mTORC2. Although SR-BI also mediates membrane 
cholesterol efflux, it remains to investigate the influence of SR-BI on membrane cholesterol efflux 
in TAMs and whether reprogramming of TAMs affects tumorigenesis through SR-BI. Although 
recent studies indicated SR-BI as a potential marker for cancer diagnosis and prognosis [17], it is 
important to further explore the role of SR-BI in cancer development, and investigate whether SR-
BI could be used as a target to treat cancer in the future. 
 
The SR-BI protein expression can be regulated by transcriptional factors, endogenous factors, 
miRNAs, and its accessory proteins (NHERF1, NHERF2, PDZK1/NHERF3) at the transcriptional, 
post-transcriptional, or post-translational levels. The transcriptional factors regulating SR-B1 
expression include LXRα/β, PPARα/γ, FXR, RXR, SREBP-1a/1c/2, ER-α/β, SF-1, HNF4α, LRH-
1, PREB, FoxO1/3/4, DAX-1, YY-1, PXR and STAT1/2. Endogenous factors regulating SR-B1 
expression include hormones (ACTH, glucocorticoids, Ang II, insulin, IGF-1, PAPP-A, TRβ, HL, 
testosterone and leptin), cytokine IFNα, LGF, HSL, and glucose. The regulation of SR-BI 
expression mediated by transcriptional factors and endogenous factors is very complicated. Some 
transcriptional factors (such as LXR and PPAR) and endogenous factors (such as ACTH) regulate 
SR-BI expression not only at the transcriptional level, but also at the post-transcriptional level. 
Additionally, the regulating effects of some factors (such as LXR, PPAR, FXR, ER, glucocorticoids) 
on SR-BI expression were inconsistent in literatures, which might be due to the different cell types 
and different animal models used. The detailed mechanisms of action of many factors regulating 
SR-BI expression are not clear and need further studies. Recently, several miRNAs, including 
miR-24, miR-96, miR-125a, miR-185, miR-217, miR-223, and miR-455, have been found to 
regulate the SR-BI expression. It remains to further explore other miRNA regulating SR-BI 
expression. Another kind of ncRNA, long ncRNAs (lncRNA), have also been proposed as a new 
layer of gene regulation, however, up to now there are no studies to report lncRNAs regulating 
SR-BI expression. In addition, there are no studies to focus on the role of this kind of factors on 
SR-BI expression in tumor tissues or cells. Accessory proteins, PDZK1/NHERF3, NHERF1 and 
NHERF2, can interact with SR-BI and regulate the expression of SR-BI at the post-translational 
level [17]. Decrease in PDZK1 strongly down-regulated the SR-BI expression in liver, kidney and 
gut, while NHERF1 and NHERF2 overexpression down-regulated the SR-BI protein expression 
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in liver and steroidogenic tissues/cells. It would be very interesting to investigate the changes of 
these factors in cancer tissues and cells, and further investigate their effect on SR-BI expression 
in cancer. 
 
Natural products have been proven to be a promising pool for drug discovery. In this review, we 
summarized the identified natural products that regulate SR-BI expression, including polyphenols, 
alkaloids, terpenoids, unsaturated fatty acid, and polysaccharides. The natural products from 
polyphenols group reported to regulate SR-BI expression include quercetin, kaempferol, catechin, 
PGG, apigenin-7-O-β-D-glucuronide, luteolin, caffeic acid, ferulic acid, ellagic acid, resveratrol. In 
addition, caffeine, berberine, trimethylglycine, 19-methoxy-9,15-ene-puupehenol, 20-methoxy-
9,15-ene-puupehenol, β-carotene, DHA, EPA, 13-hydroxy linoleic acid, oleic acid, guar gum, and 
chenodeoxycholic acid from other groups were reported to regulate SR-BI expression. At present, 
most of the natural products regulating SR-BI expression were identified incidentally by studies 
examining lipid metabolism. There are no systematic studies screening the effect of natural 
products on SR-BI expression. In many cases the detailed molecular mechanisms of the studied 
natural products remain elusive or are just deduced from coincidental observations lacking 
experimental proof of causality. Thus, in-depth and stringent molecular analyses of active natural 
products may discover new strategies for the treatment or prevention of human diseases involving 
SR-BI, including cancer. 
 
SR-BI plays a very important role in regulation of cholesterol metabolism in humans. In clinical 
studies, polyphenols were reported to exhibit the beneficial effects on hyperlipidemia while 
contrary opinions also exist. For example, supplementation of flavonoid-rich grape seed extracts 
and black/green tea, pycnogenol as well as red wine polyphenols were found to have a beneficial 
effect on plasma lipoprotein and cholesterol. On the contrary, some studies indicated that there 
was no relationship between polyphenol consumption and the risk of CVD or cholesterol profile. 
Interestingly, clinical trials have reported that supplementation of polyphenols-rich grape skin 
extract and flavonoids could reduce biochemically recurrent prostate cancer and ovarian cancer 
risk, respectively. Systematic reviews and meta-analyses studies have consistently demonstrated 
administration of alkaloid berberine reduced total cholesterol, triglycerides and LDL cholesterol 
levels in humans [248]. Moreover, a higher betaine intake was associated with lung cancer [250] 
and liver cancer [251].  Unsaturated fatty acid omega-3 fatty acids consumption increased in LDL-
cholesterol [267, 268], while OM-3A EE significantly reduced TG levels and VLDL-cholesterol 
levels compared with placebo in humans [269]. Omega-3 fatty acids DHA and EPA were reported 
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to exhibit therapeutic effects on breast cancer and colorectal aberrant crypt foci, respectively [270, 
271]. However, all these clinical studies are not able to prove whether the therapeutic effects of 
these natural products are due to their regulation of SR-BI expression or not. 
 
Future directions in studying the SR-BI as a target of natural products and its significance in 
cancer include: 
 
**Further understanding the role of SR-BI in cancer development. Recent studies indicated 
SR-BI as a potential marker for cancer diagnosis and prognosis in humans [17], and plays an 
important role in cancer cell proliferation and apoptosis in vitro studies, but it is important to further 
confirm whether SR-BI could be used as an useful target to treat cancer in vivo and finally in 
humans. 
 
**Further understanding the regulatory mechanisms of SR-BI expression in cancer 
development by new biotechnologies. Although significant progress has recently been made 
in characterizing regulatory mechanisms of SR-BI, there are very limited studies to focus on its 
regulatory mechanisms in tumor tissues or cells. At present, new biotechnologies including RNA-
sequencing, lncRNA arrays, RNA interference (RNAi) or CRISPR/Cas9 library screening, has 
empowered the discovery of new epigenetic regulators (such as lncRNAs) that are associated 
with or regulate SR-BI expression [278]. Further investigation of the role of these new regulators 
will provide us a clear picture of how SR-BI expression is regulated in cancer development and 
can be therapeutically targeted. 
 
**Systematic studies screening of natural products targeting SR-BI expression in cancer 
models. Natural products have been proven to be a promising pool for drug discovery. At present, 
most of the natural products regulating SR-BI expression were identified incidentally by studies 
examining lipid metabolism. There are no systematic studies screening the effect of natural 
products on SR-BI expression. To identify potential drug leads with capability of regulating SR-BI 
expression in cancer cells or tissues from such large pool, it is important to do systematic 
screening of natural products targeting SR-BI expression in cancer models by high throughput 
drug screening platforms. 
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Figure 1. Role of scavenger receptor class B type I (SR-BI) in preventing macrophage foam cell 
formation by promoting cholesterol metabolism. Three main proteins, including SR-BI, ATP-
binding cassette transporter A1 (ABCA1), and ABCG1, mediate the efflux of free cholesterol (FC) 
in macrophages. SR-BI transports cholesterol to high-density lipoprotein (HDL), whereas ABCA1 
effluxes cholesterol to lipid-poor apolipoprotein AI (apoAI) or to apoE which is released by 
macrophages. There are two pathways to clear cytoplasmic cholesteryl ester (CE): (i) CE is 
converted by neutral CE hydrolase (NCEH) and the FC transported to the plasma membrane for 
efflux; (ii) cytoplasmic CE is also trafficked into autophagosomes that fuse with lysosomes, where 
the CE is converted into cholesterol by lysosomal acid lipase (LAL) and the FC transported for 








Figure 2. Effects of natural products, transcription factors and LcnRNAs on SRBI expression and 
reprogramming of tumor-associated macrophages (TAM) through cholesterol efflux in tumor 
progression. Natural products, transcription factors and LncRNAs regulate the expression of SR-
BI, which controls the cholesterol ester uptake in cancer cells. Tumor cell-derived hyaluronic acid 
(HA) promotes ABCA1-ABCG1-mediated membrane cholesterol efflux in TAM and causes the 
reprogramming of TAM through p-Akt/STAT3 pathway. IL-4-induced gene expression in TAMs is 
related to tumor-promoting functions, including increased arginine metabolism and promoting 












Figure 3. Regulatory mechanisms of SR-BI expression at transcriptional and post-transcriptional 
and post-translational levels, as well as targets by which natural products regulate SR-BI 
expression. At the transcriptional level, SR-BI protein expression is regulated by a variety of 
molecules, including transcription factors (LXRα/β, PPARα/γ, FXR, RXR, SREBP-1a/1c/2, ER-
α/β, SF-1, HNF4α, LRH-1, PREB, FoxO1/3/4, DAX-1, YY-1, PXR and STAT1/2), hormones 
(ACTH, glucocorticoids, Ang II, insulin, IGF-1, PAPP-A, TRβ, HL, testosterone and leptin), 
miRNAs (miR-24, miR-96, miR-125a, miR-185, miR-217, miR-223, and miR-455), and SR-BI 
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Table 2. The factors regulating SR-BI expression 
 
Factors Cellular models 





LXRα and β ↑SR-BI transcription in human and 
murine hepatoma cell lines, and in 
3T3-L1 preadipocytes [97]. 
↓SR-BI in Caco-2/TC7 cells via a post-
transcriptional mechanism [98]. 
↑mRNA and protein levels of SR-BI 
in hamster liver [99]. 
↓SR-BI protein, not mRNA levels in 
hepatic membranes of C57Bl/6J 
mice [100]. 
PPARα ↑SR-BI levels in rat hepatocytes and 
HepG2 hepatoma cells, as well as 
liver endothelial cells [103]. 
↑Hepatic SR-BI expression in 
hamsters [104], and in 
atherosclerotic lesions of apoE-
deficient mice [105].  
↓SR-BI protein expression in the 
liver in both wild-type C57BL/6 
mice [106] and PDZK1-deficient 
mice [107].  
No change in SR-BI mRNA level in 
circulating mononuclear cells in 
humans [108]. 
PPARγ ↑SR-BI expression in rat hepatocytes, 
endothelial cells, Hepa 1c1c-7 and 
Kupffer cells [103], as well as in 
HepG2 [109]. 
↑SR-BI protein expression in 
adipose tissue, but not liver in 
C57BL/6 mice [110], as well as in 
atherosclerotic lesions of apoE-
deficient mice [105]. 
 
56 
FXR ↑mRNA and protein levels of hepatic 
SR-BI [115]. 
↓SR-BI expression in hepatocytes 
[111], and Huh7.5 cells [114]. 
 
↑hepatic SR-BI mRNA and protein 
levels in hyperlipidemic hamsters, 
but not in normolipidemic hamsters 
[116]. 
RXR ↑SR-BI mRNA in HUVECs [120]. N.A.1) 
SREBP-1a and 
c 
↑SR-BI gene expression by activation 
of SREBP-1a [123]. 
↓hepatic SR-BI in SREBP-1a and -
1c transgenic mice on normal chow 
[125]. 
SREBP-2 ↑SR-BI mRNA and protein levels in 
transfected HEK293 and HepG2 cells 
[124]. 
N.A. 
ER ↑SR-BI promoter activity by activation 
of ER-α and -β by binding to  ER 
element [123]. 
↓Endothelial SR-BI in human coronary 
artery endothelial cells [129]. 
↑SR-BI in the adrenal gland and 
corpus luteal cells of the ovary in 
rats [127]. 
↓SR-BI in the liver and the ovary in 
rats [127]. 
 
SF-1 ↑SR-BI gene expression in both 
human HTB9 bladder carcinoma and 
mouse Y-1 tumor cells [132]. 
No SR-BI mRNA in the gonadal 
ridge of day 11.5 SF-1 KO embryos 
[133]. 
HNF4α ↑SR-BI expression at both mRNA and 
protein levels in cultured hepatocytes 
[134]. 
↑SR-BI mRNA and protein levels in 
the liver in rat 
LRH-1 ↑SR-BI expression in vitro [135]. ↓SR-BI mRNA levels in livers of the 
heterozygous LRH-1-KO mice 
[135]. 
57 
PREB ↑SR-BI protein in the adrenocortical 
cell line Y-1 [137]. 
N.A. 
FoxO N.A. ↓hepatic SR-BI expression in the 
mice with liver-specific triple FoxO 
KO (FoxO1,3,4) [138]. 
DAX-1 ↓SR-BI promoter activity in 
transfected adrenal Y-1, HTB-9, and 
HepG2 cells [139]. 
N.A. 
YY-1 ↓activity of the SR-BI promoter in 
transfected HTB9 cells [141]. 
N.A. 
PXR ↓SR-BI in HepG2 cells and in primary 
rat hepatocytes [142]. 
↓hepatic SR-BI level in ApoE3-
Leiden (E3L) and E3L.CETP mice 
[143]. 
STAT ↓SR-BI promoter activity upon 
mutagenesis of a STAT1/STAT2 
response element in the SR-BI 
promoter [137]. 
N.A. 




ACTH ↑SR-BI protein and mRNA expression 
in the cultured murine Y1-BS1 adrenal 
cells [17]. 
↑SR-BI protein expression in 
adrenal glands in C57BL/6 mice 
[147]. 
Glucocorticoid ↓SR-BI expression in adrenocortical 
H295R and ovarian SKOV-3 cells 
[150]. 
↑SR-BI mRNA expression in primary 
rat hepatocytes by a glucocorticoid 
dexamethasone [151]. 
↓SR-BI gene expression in 
adrenals of corticosterone-
deficient mice [150]. 
58 
No effect in HepG2 cells and THP-1 
macrophages treatment with 
dexamethasone [151]. 
Angiotensin II ↓SR-BI expression in human umbilical 
vein endothelial cells [152], and the 
mouse proximal tubular cell line MCT 
cells [153]. 
↑SR-BI mRNA and protein expression 
in the human adrenocortical 
carcinoma cell line NCI-H295R cells 
[154]. 
↓SR-BI protein expression in 
isolated tubules of rats [153]. 
Insulin ↑SR-BI mRNA and protein levels in 
polarized CaCo-2 cells [155]. 
↑SR-BI expression in all intestinal 
segments in two diet-induced 
animal models of insulin resistance 
(fructose-fed hamster and high-fat-
fed mouse) [156]. 
IGF-1 ↓SR-BI mRNA and protein levels in 
THP-1-derived macrophages [157], 
and in cultured HepG2 cells [158]. 
↓SR-BI mRNA level in rats [158]. 
PAPP-A ↓SR-BI expression in THP-1 
macrophage-derived foam cells [158]. 
↑SR-BI expression in both aorta 
and peritoneal macrophages in 
apoE-deficient mice with PAPP-A 
knockdown [159]. 
TRβ ↑SR-BI expression [160]. N.A. 
HL ↑SR-BI expression in adrenal gland in 
mice when inhibition of HL [161, 162]. 
N.A. 
Testosterone ↑SR-BI mRNA and protein levels in 
both cultivated HepG2 cells and 
primary human monocyte-derived 
macrophages (HMDMs) [163]. 
N.A. 
59 
Leptin N.A. ↑hepatic SR-BI protein and mRNA 
levels in leptin-deficient mice [164]. 
IFNα ↓SR-BI expression in HepG2 [144]. N.A. 
cAMP ↑SR-BI mRNA expression in 
transfected 293T cells, human 
granulosa SVOG-4o cells, and in 
primary cultures of rat theca-interstitial 
cells [166]. 
N.A. 
LGF N.A. ↑SR-BI protein level in ethane 
dimethanesulfonate (EDS)-treated 
rats [167]. 
HSL N.A. ↑SR-BI protein expression, but not 
mRNA levels in the testis of 
hormone-sensitive lipase (HSL) 
KO male mice [168]. 
Glucose ↓SR-BI mRNA and protein levels in 
HMDMs [169], Caco-2/15 cells [170], 
and HepG2 cells [171] upon treatment 
with high glucose (25-30 mM). 
↑SR-BI mRNA and protein expression 
in J774A.1 macrophage-like cells 
upon treatment with high glucose (30 
mM) [172]. 
No changes in SR-BI abundance in 
polarized CaCo-2 cells upon 
treatment with high glucose [155]. 
↑SR-BI mRNA and protein 
expression in mouse peritoneal 
macrophages (MPM) harvested 
from C57Bl/6 diabetic mice, 
compared to MPM from control 
non-diabetic mice [172]. 





miR-24 ↓SR-BI protein expression in HepG2, 
THP-1 cells [173], steroidogenic cells 
MLTC and Y-1, and HepG2 cells 
[174]. 
↓hepatic SR-BI expression in 
apoE-deficient mice [173]. 
miR-96 ↓level of SR-BI expression in HepG2 
cells [175]. 
↑SR-BI in the liver of apoE-
deficient mice with a high fat diet 
(HFD) when decrease of miR-96 
[175]. 
miR-125a ↓mRNA and protein levels of SR-BI in 
the rat Leydig tumor R2C cells, the 
cAMP-sensitive MLTC cells [176], and 
mouse hepatic cell line Hepa 1-6 
[176], as well as mouse and rat liver 
cells [176]. 
N.A. 
miR-185 ↓level of SR-BI expression in HepG2 
cells [175]. 
↑SR-BI in the liver of apoE-
deficient mice with a HFD when 
decrease of miR-185 [175]. 
miR-217 N.A. ↓SR-BI mRNA levels in apoE-
deficient mice [177]. 
miR-223 ↓level of SR-BI expression in HepG2 
cells [175]. 
 
miR-455 ↓mRNA and protein levels of SR-BI in 
the rat Leydig tumor R2C cells and the 
cAMP-sensitive MLTC cells [176].  
Does not influence expression of SR-
BI in mouse and rat liver cells [176]. 
N.A. 





NHERF1 ↓SR-BI protein expression in liver and 
steroidogenic cells [180]. 
↓SR-BI protein expression in liver 
and steroidogenic tissues [180]. 
NHERF2 ↓SR-BI protein expression in liver and 
steroidogenic cells [180]. 
↓SR-BI protein expression in liver 
and steroidogenic tissues [180]. 
PDZK1/NHERF3 ↑SR-BI expression at the post-
translational level in vitro [17]. 
↓SR-BI protein expression in 
PDZK1-deficient mice in the liver 
and the proximal intestine [178]. 
Not affected SR-BI expression in 
steroidogenic organs in mice [178]. 

























Table 3. Natural products regulating SR-BI expression 
 
Classification Sub-classes Compounds Structures References 







































































































Bile acids Primary bile 
acids 
Chenodeoxychol
ic acid 
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